In March 2022, nivolumab (anti‐PD‐1 inhibitor) plus relatlimab received its first approval in the USA for the treatment of unresectable or metastatic melanoma in adult patients and pediatric patients aged ≥12 years who weigh ≥40 kg. This evidence concerns the gene SNCA and metastatic melanoma.